Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
AVEO PHARMACEUTICALS, INC. (AVEO)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 30.4 | 25.3 | 20.9 | 17.6 | 15.2 | 7.6 | 1.9 | 0.9 |
| Revenue growth | 100.7% | 234.9% | 989.6% | 1891.6% | 321.5% | 908.8% | 144.9% | 16.0% |
| Cost of goods sold | 4.0 | 3.1 | 2.4 | 4.7 | 1.7 | 0.8 | 0.1 | 0.0 |
| Gross profit | 26.5 | 22.2 | 18.5 | 12.9 | 13.4 | 6.7 | 1.8 | 0.9 |
| Gross margin | 87.0% | 87.9% | 88.4% | 73.2% | 88.5% | 89.1% | 92.8% | 100.0% |
| Selling, general and administrative [+] | 17.6 | 17.1 | 17.3 | 15.7 | 15.1 | 14.9 | 15.1 | 9.0 |
| General and administrative | | | | 15.7 | | | | 9.0 |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 11.1 | 12.3 | 10.2 | 6.1 | 7.5 | 6.9 | 5.8 | 4.6 |
| Other operating expenses | | | | -2.7 | | | | 4.9 |
| EBITDA [+] | -2.2 | -7.1 | -9.0 | -6.1 | -9.2 | -15.0 | -19.1 | -17.6 |
| EBITDA growth | -76.6% | -52.6% | -52.9% | -65.1% | 14.2% | 103.3% | 78.3% | -3.5% |
| EBITDA margin | -7.1% | -28.2% | -43.0% | -34.8% | -60.6% | -199.2% | -994.7% | -1984.4% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -2.2 | -7.2 | -9.0 | -6.2 | -9.2 | -15.1 | -19.1 | -17.6 |
| EBIT growth | -76.5% | -52.5% | -52.9% | -65.0% | 14.3% | 103.4% | 78.4% | -3.4% |
| EBIT margin | -7.1% | -28.3% | -43.1% | -34.9% | -60.7% | -199.4% | -995.6% | -1985.8% |
| Non-recurring items | | | | | | | | -4.9 |
| Interest expense | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 0.6 | 0.5 |
| Interest expense | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 0.6 | 0.5 |
| Other income (expense), net [+] | | | | 0.1 | | 2.6 | -2.4 | 1.7 |
| Unrealized gain/loss on derivatives | | | | | | 2.6 | -2.4 | 1.7 |
| Pre-tax income | -3.3 | -8.3 | -10.2 | -7.3 | -10.4 | -13.6 | -22.1 | -11.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -3.3 | -8.3 | -10.2 | -7.3 | -10.4 | -13.6 | -22.1 | -11.5 |
| Net margin | -10.7% | -32.9% | -48.8% | -41.1% | -68.3% | -179.9% | -1152.2% | -1298.4% |
| |
| Basic EPS [+] | ($0.09) | ($0.24) | ($0.30) | ($0.21) | ($0.30) | ($0.40) | ($0.81) | ($0.44) |
| Growth | -68.7% | -39.1% | -63.3% | -51.9% | -7.3% | -6.0% | 54.8% | 50.6% |
| Diluted EPS [+] | ($0.09) | ($0.24) | ($0.30) | ($0.21) | ($0.30) | ($0.40) | ($0.81) | ($0.44) |
| Growth | -68.7% | -39.1% | -63.3% | -51.9% | -7.3% | -6.0% | 54.8% | 352.7% |
| |
| Shares outstanding (basic) [+] | 34.6 | 34.5 | 34.5 | 34.4 | 34.4 | 34.4 | 27.4 | 26.3 |
| Growth | 0.7% | 0.4% | 25.7% | 31.0% | 33.2% | 97.9% | 70.6% | 71.2% |
| Shares outstanding (diluted) [+] | 34.6 | 34.5 | 34.5 | 34.4 | 34.4 | 34.4 | 27.4 | 26.3 |
| Growth | 0.7% | 0.4% | 25.7% | 31.0% | 33.2% | 97.9% | 70.6% | -43.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|